PT  - JOURNAL ARTICLE
AU  - Chayada Piantham
AU  - Natalie M. Linton
AU  - Hiroshi Nishiura
AU  - Kimihito Ito
TI  - Estimating the elevated transmissibility of the B.1.1.7 strain over previously circulating strains in England using GISAID sequence frequencies
AID  - 10.1101/2021.03.17.21253775
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.17.21253775
4099  - http://medrxiv.org/content/early/2021/06/13/2021.03.17.21253775.short
4100  - http://medrxiv.org/content/early/2021/06/13/2021.03.17.21253775.full
AB  - The B.1.1.7 strain, also referred to as Alpha variant, is a variant strain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The Alpha variant is considered to possess higher transmissibility compared to the strains previously circulating in England. This paper proposes a new method to estimate the selective advantage of a mutant strain over another strain using the time course of strain frequencies and the distribution of the serial interval of infections. This method allows the instantaneous reproduction numbers of infections to vary over calendar time. The proposed method also assumes that the selective advantage of a mutant strain over previously circulating strains is constant. Applying the method to SARS-CoV-2 sequence data from England, the instantaneous reproduction number of the B.1.1.7 strain was estimated to be 26.6–45.9% higher than previously circulating strains in England. This result indicates that control measures should be strengthened by 26.6–45.9% when the B.1.1.7 strain is newly introduced to a country where viruses with similar transmissibility to the preexisting strain in England are predominant.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Japan Agency for Medical Research and Development (grant numbers JP20fk0108535). The work was also supported by the Grant-in-Aid (grant number 21H03490) and by the World-leading Innovative and Smart Education Program (1801) both from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSupplementary Table S1 contains the dataset used in the analysis.